Modeling for risk assessment of neurotoxic effects.

The regulation of noncancer toxicants, including neurotoxicants, has usually been based upon a reference dose (allowable daily intake). A reference dose is obtained by dividing a no-observed-effect level by uncertainty (safety) factors to account for intraspecies and interspecies sensitivities to a chemical. It is assumed that the risk at the reference dose is negligible, but no attempt generally is made to estimate the risk at the reference dose. A procedure is outlined that provides estimates of risk as a function of dose. The first step is to establish a mathematical relationship between a biological effect and the dose of a chemical. Knowledge of biological mechanisms and/or pharmacokinetics can assist in the choice of plausible mathematical models. The mathematical model provides estimates of average responses as a function of dose. Secondly, estimates of risk require selection of a distribution of individual responses about the average response given by the mathematical model. In the case of a normal or lognormal distribution, only an estimate of the standard deviation is needed. The third step is to define an adverse level for a response so that the probability (risk) of exceeding that level can be estimated as a function of dose. Because a firm response level often cannot be established at which adverse biological effects occur, it may be necessary to at least establish an abnormal response level that only a small proportion of individuals would exceed in an unexposed group. That is, if a normal range of responses can be established, then the probability (risk) of abnormal responses can be estimated.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  R L Kodell,et al.  Upper confidence limits on excess risk for quantitative responses. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[2]  D W Gaylor,et al.  Incidence of developmental defects at the no observed adverse effect level (NOAEL). , 1992, Regulatory toxicology and pharmacology : RTP.

[3]  D. Barnes,et al.  Reference dose (RfD): description and use in health risk assessments. , 1988, Regulatory toxicology and pharmacology : RTP.

[4]  W. Slikker,et al.  Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). , 1988, Toxicology and applied pharmacology.

[5]  D W Gaylor,et al.  Issues in qualitative and quantitative risk analysis for developmental toxicology. , 1988, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  K S Crump,et al.  A new method for determining allowable daily intakes. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[7]  David W. Gaylor,et al.  Dose-response modeling of quantitative response data for risk assessment , 1992 .

[8]  W Slikker,et al.  Risk assessment for neurotoxic effects. , 1990, Neurotoxicology.

[9]  W. Slikker,et al.  Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. , 1989, Neurotoxicology.